<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838392</url>
  </required_header>
  <id_info>
    <org_study_id>US-312-01</org_study_id>
    <nct_id>NCT04838392</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus</brief_title>
  <official_title>Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionime Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionime Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of the RIGHTEST&#xD;
      Continuous Monitoring (CGM) System in adult population with diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, non-randomized, multicenter, single-arm pivotal study&#xD;
      without a control group. In total, 150 subjects with type 1 or type 2 diabetes will be&#xD;
      enrolled at 16 investigational sites in the United States. All subjects are required to wear&#xD;
      1 Sensor on the back of each upper arm for up to 14 days (up to 336 hours) and participate in&#xD;
      both study visit and home use portion in this study. All subjects will have venous blood&#xD;
      draws for evaluation of the blood glucose reference measurements in in-clinic visits, and to&#xD;
      collect accuracy information against a laboratory reference method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All information as provided by CGM system will be masked from subjects and study team during the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>RIGHTEST Continuous Glucose Monitoring System Performance</measure>
    <time_frame>14 days</time_frame>
    <description>The CGM System performance will be evaluated in terms of point and trend accuracy of CGM System readings comparted to the reference measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RIGHTEST Glucose Monitoring System Related Adverse Device Effects</measure>
    <time_frame>14 days</time_frame>
    <description>The CGM System will be characterized by Adverse Device Effects experienced by study participants.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CGM System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood draw and glucose challenge will be performed to evaluate performance of CGM system compared to reference measurement during in in-clinic visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RIGHTEST Continuous Glucose Monitoring System</intervention_name>
    <description>RIGHTEST Continuous Glucose Monitoring System</description>
    <arm_group_label>CGM System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be at least 18 years of age.&#xD;
&#xD;
          -  Subjects must have type 1 or type 2 diabetes mellitus.&#xD;
&#xD;
          -  Subjects must be available to participate in all study visits.&#xD;
&#xD;
          -  Willing to wear 1 Sensor on each upper arm simultaneously.&#xD;
&#xD;
          -  Subjects must be willing and able to provide signed written consent.&#xD;
&#xD;
          -  Subjects must be able to read and understand the device instructions.&#xD;
&#xD;
          -  Subjects must be able to speak, read and write English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.&#xD;
&#xD;
          -  Extensive skin changes or diseases at the proposed application sites.&#xD;
&#xD;
          -  Subjects who have or are:&#xD;
&#xD;
               -  Pregnant,&#xD;
&#xD;
               -  A hematocrit level &gt;37%,&#xD;
&#xD;
               -  A condition requiring or likely requiring magnetic resonance imaging (MRI),&#xD;
                  computerized tomography (CT) or diathermy scheduled during the study,&#xD;
&#xD;
          -  Participated in another clinical trial within 2 weeks prior to screening or are&#xD;
             intending to participate in another clinical trial during the study.&#xD;
&#xD;
          -  Unsuitable for participation due to any other cause as determined by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Lakeview Clinical Research</name>
      <address>
        <city>Guntersville</city>
        <state>Alabama</state>
        <zip>35976</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novak Clinical Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research, LLC</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. De Armas Research Center, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>11373</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RNA America,LLC</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infinite Clinical Trials</name>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L-MARC Research Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Integrity, LLC.</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott Research,Inc</name>
      <address>
        <city>Laurelton</city>
        <state>New York</state>
        <zip>11413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Research Center of the Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Trials WorldWide</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

